US Bancorp DE Sells 242 Shares of BeiGene, Ltd. (NASDAQ:BGNE)

US Bancorp DE lessened its position in BeiGene, Ltd. (NASDAQ:BGNE) by 55.9% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 191 shares of the company’s stock after selling 242 shares during the period. US Bancorp DE’s holdings in BeiGene were worth $41,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of BeiGene by 3.8% in the 1st quarter. BlackRock Inc. now owns 2,699,444 shares of the company’s stock valued at $509,114,000 after purchasing an additional 98,316 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of BeiGene by 3.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 461,093 shares of the company’s stock valued at $101,413,000 after purchasing an additional 13,676 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of BeiGene by 4.1% in the 4th quarter. Bank of America Corp DE now owns 314,007 shares of the company’s stock valued at $69,063,000 after purchasing an additional 12,501 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of BeiGene by 10.9% in the 2nd quarter. Legal & General Group Plc now owns 284,661 shares of the company’s stock valued at $46,072,000 after purchasing an additional 27,945 shares in the last quarter. Finally, Capital Group Private Client Services Inc. boosted its stake in shares of BeiGene by 74.2% in the 1st quarter. Capital Group Private Client Services Inc. now owns 275,197 shares of the company’s stock valued at $51,902,000 after purchasing an additional 117,231 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

Insiders Place Their Bets

In other BeiGene news, insider Lai Wang sold 462 shares of the firm’s stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $224.74, for a total transaction of $103,829.88. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, insider Lai Wang sold 462 shares of BeiGene stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $224.74, for a total value of $103,829.88. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Julia Aijun Wang sold 472 shares of BeiGene stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $179.55, for a total transaction of $84,747.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,698,127 shares of company stock worth $556,876,818. Company insiders own 7.40% of the company’s stock.

BeiGene Stock Performance

Shares of BGNE stock opened at $208.92 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 3.13 and a quick ratio of 2.90. The stock has a market cap of $20.20 billion, a PE ratio of -12.54 and a beta of 0.69. The stock has a 50-day moving average of $196.28 and a 200-day moving average of $219.12. BeiGene, Ltd. has a one year low of $124.46 and a one year high of $280.62.

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings results on Wednesday, August 2nd. The company reported ($3.64) EPS for the quarter, missing analysts’ consensus estimates of ($3.47) by ($0.17). The company had revenue of $595.30 million during the quarter, compared to the consensus estimate of $501.07 million. BeiGene had a negative net margin of 95.67% and a negative return on equity of 40.78%. The business’s revenue was up 74.3% compared to the same quarter last year. During the same period last year, the company earned ($5.56) earnings per share. As a group, sell-side analysts expect that BeiGene, Ltd. will post -12.59 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. JPMorgan Chase & Co. upped their price target on shares of BeiGene from $297.00 to $300.00 and gave the stock an “overweight” rating in a research report on Monday, August 7th. Citigroup assumed coverage on shares of BeiGene in a research report on Monday, July 17th. They set a “buy” rating and a $275.00 price target on the stock. 3M restated a “downgrade” rating on shares of BeiGene in a research report on Friday, June 30th. 22nd Century Group restated a “downgrade” rating on shares of BeiGene in a research report on Friday, June 30th. Finally, StockNews.com assumed coverage on shares of BeiGene in a research report on Thursday, August 17th. They set a “hold” rating on the stock. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $279.39.

BeiGene Company Profile

BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).